Investigational drug · Phase 3
Semagludtide
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity & Overweight, Early Alzheimer's Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Semagludtide"
First trial start
2021
May 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Semagludtide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity & Overweight
- Early Alzheimer's Disease
Approved drugs for the same conditions: Obesity and weight management · Alzheimer's disease · Cardiovascular and metabolic · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Semagludtide" as an intervention, largest first.
- A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04777396 · 1,840 participants · Start May 18, 2021 · Primary completion Sep 16, 2025
Drug: Semagludtide; Placebo (semaglutide) · For: Early Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Sun City, Arizona · 447 sites in all
- Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese AdultsPivotal-lookingNot yet recruiting
Lumos PharmaIndustry
NCT07754045 · 202 participants (planned) · Start Feb 15, 2027 · Primary completion Feb 15, 2028
Drug: LUM-201; Placebo and 1 more · For: Obesity & Overweight
- Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesPivotal-lookingCompleted
Zagazig UniversityGovernment (non-federal)
NCT07834398 · 150 participants · Start Nov 14, 2025 · Primary completion Apr 13, 2026
Drug: Dulaglutide; Semagludtide and 1 more · For: Non-diabetec Obesity; Obesity (Disorder)
Sites: Najran, Saudi Arabia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity & Overweight
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LUM-201Phase 36 trials
Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight
- HDM1005 1Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Obesity & Overweight
- HDM1005 2Phase 34 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Obesity & Overweight
- EnobosarmPhase 22 trials
Veru Inc. · Obesity & Overweight, Mobility Disability, HOMA-IR
- BIO101Phase 21 trial
Biophytis · Muscle Wasting, Obesity & Overweight, Obesity
- ERX1000Phase 21 trial
ERX Pharmaceuticals · Obesity & Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.